PDT Partners LLC Has $217,000 Stock Holdings in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

PDT Partners LLC trimmed its position in Treace Medical Concepts, Inc. (NASDAQ:TMCI) by 54.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,163 shares of the company’s stock after selling 34,786 shares during the quarter. PDT Partners LLC’s holdings in Treace Medical Concepts were worth $217,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Quantbot Technologies LP acquired a new position in shares of Treace Medical Concepts during the 4th quarter worth $69,000. Dynamic Technology Lab Private Ltd bought a new position in Treace Medical Concepts in the fourth quarter valued at about $77,000. Boothbay Fund Management LLC acquired a new position in Treace Medical Concepts during the fourth quarter worth about $90,000. AlphaQuest LLC bought a new position in shares of Treace Medical Concepts in the fourth quarter worth about $91,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Treace Medical Concepts by 22.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,056 shares of the company’s stock valued at $142,000 after purchasing an additional 3,452 shares in the last quarter. 84.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Treace Medical Concepts

In other Treace Medical Concepts news, insider Sean F. Scanlan sold 50,000 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $7.97, for a total transaction of $398,500.00. Following the sale, the insider now owns 364,081 shares of the company’s stock, valued at approximately $2,901,725.57. This represents a 12.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 27.72% of the company’s stock.

Treace Medical Concepts Trading Down 1.1 %

Shares of TMCI stock opened at $7.26 on Friday. The stock has a 50-day moving average of $7.76 and a 200-day moving average of $7.88. The company has a current ratio of 4.12, a quick ratio of 2.98 and a debt-to-equity ratio of 0.51. The stock has a market cap of $456.58 million, a price-to-earnings ratio of -7.33 and a beta of 0.77. Treace Medical Concepts, Inc. has a 1-year low of $3.92 and a 1-year high of $11.33.

Analyst Ratings Changes

Several research analysts have recently issued reports on TMCI shares. Truist Financial lowered their price target on shares of Treace Medical Concepts from $9.50 to $8.00 and set a “hold” rating for the company in a report on Friday, April 11th. BTIG Research upgraded Treace Medical Concepts from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research report on Tuesday, February 4th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Treace Medical Concepts has an average rating of “Hold” and a consensus target price of $9.93.

Treace Medical Concepts Profile

Treace Medical Concepts, Inc, a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity.